Helmut Butzkueven

Projects

Projects per year 2005 2018 2019 2021 2034

• 12 Active
• 32 Finished

Projects per year

Search results

• Finished

  Support of MS - Monash PHD Research Assistant

  Jokubaitis, V. & Butzkueven, H.

  Trustee for Mark Pennycook Foundation

  19/06/23 → 18/06/24

  Project: Research

• Genetics group research and CTLA4 and MS project

  Jokubaitis, V. & Butzkueven, H.

  Australian Communities Foundation (trading as Melbourne Community Foundation)

  3/10/22 → 3/10/23

  Project: Research

• Personalised Therapy for Multiple Sclerosis

  Jokubaitis, V. & Butzkueven, H.

  3/06/22 → 3/06/23

  Project: Research

• The contribution of monocytes and P2X7 Receptor in Multiple Sclerosis relapse.

  Monif, M., Butzkueven, H., O'Brien, T. & Stankovich, J.

  2/02/22 → 31/12/23

  Project: Research

• Determining the risk of cervical precancer and cancer in women with multiple sclerosis: a national data linkage study.

  Van Der Walt, A. (Primary Chief Investigator (PCI)), Jokubaitis, V. (Chief Investigator (CI)), Butzkueven, H. (Chief Investigator (CI)), Taylor, B. V. (Chief Investigator (CI)), Lechner-Scott, J. (Chief Investigator (CI)) & Brotherton, J. M. L. (Chief Investigator (CI))

  Multiple Sclerosis Research Australia (trading as National Multiple Sclerosis Research Foundation Limited)

  1/01/22 → 31/12/24

  Project: Research

• InforMS – an electronic patient-driven health care model with digital biomarker monitoring that improves the clinical care of people with MS

  van der Mei, I. (Primary Chief Investigator (PCI)), Butzkueven, H. (Chief Investigator (CI)), Taylor, B. V. (Chief Investigator (CI)), Palmer, A. J. (Chief Investigator (CI)), Blizzard, L. (Chief Investigator (CI)) & Nicol, D. (Chief Investigator (CI))

  3/05/21 → 3/05/23

  Project: Research

• The role of monocytes and P2X7 Receptor in the pathogenesis of relapsing remitting multiple sclerosis flare: a translational study.

  Monif, M. & Butzkueven, H.

  Multiple Sclerosis Research Australia (trading as National Multiple Sclerosis Research Foundation Limited)

  18/03/21 → 31/12/23

  Project: Research

• The contribution of monocytes and P2X7 Receptor in Multiple Sclerosis relapse.

  Monif, M., Butzkueven, H., O'Brien, T. & Stankovich, J.

  2/03/21 → 31/12/21

  Project: Research

• Immune phenotyping and Disease modifying treatments in MS – implications for treatment response and infection.

  Van Der Walt, A. (Primary Chief Investigator (PCI)), Monif, M. (Chief Investigator (CI)) & Butzkueven, H. (Chief Investigator (CI))

  1/01/21 → 31/12/21

  Project: Research

• Active self-monitoring to prospectively detect treatment failure and define subclinical progression trajectories in multiple sclerosis: The ACTIVE-MS Program.

  Van Der Walt, A. (Primary Chief Investigator (PCI)), Butzkueven, H. (Chief Investigator (CI)), Jokubaitis, V. (Chief Investigator (CI)), Kolbe, S. (Chief Investigator (CI)), Vogel, A. P. (Chief Investigator (CI)), Stankovich, J. (Chief Investigator (CI)), Butler, E. (Chief Investigator (CI)), Macdonell, R. A. L. (Chief Investigator (CI)) & Darby, D. (Chief Investigator (CI))

  Trish Multiple Sclerosis Research Foundation

  1/01/20 → 31/12/23

  Project: Research

• Pharmacogenomic prediction of treatment response in multiple sclerosis

  Van Der Walt, A. (Primary Chief Investigator (PCI)), Jokubaitis, V. (Chief Investigator (CI)) & Butzkueven, H. (Chief Investigator (CI))

  21/10/19 → 20/04/20

  Project: Research

• Analysis of Real-World Long-Term Effectiveness of Ocrelizumab in Primary Progressive MS Disease

  Butzkueven, H. (Primary Chief Investigator (PCI)) & Hinson, E. (Project Manager)

  Hoffmann-La Roche (United Kingdom)

  11/09/19 → 30/11/23

  Project: Research

• Active Participatory Health Monitoring in people with Multiple Sclerosis to improve treatment outcomes (Active-MS)

  Butzkueven, H. (Primary Chief Investigator (PCI)), Van Der Walt, A. (Chief Investigator (CI)), Darby, D. (Chief Investigator (CI)), Stankovich, J. (Chief Investigator (CI)), Jokubaitis, V. (Chief Investigator (CI)), Skibina, O. (Chief Investigator (CI)), Marriott, M. (Chief Investigator (CI)), Butler, E. (Chief Investigator (CI)) & Gresle, M. (Project Manager)

  Department of Health and Aged Care (Australia)

  1/07/19 → 30/06/24

  Project: Research

• CLADIN sub study. Effect of CLADribine on Innate Immune Response (CLADIN). MS Immunity Project.

  Monif, M. (Primary Chief Investigator (PCI)), Butzkueven, H. (Chief Investigator (CI)) & O'Brien, T. (Chief Investigator (CI))

  27/06/19 → 9/09/22

  Project: Research

• A global prospective open access study to assess and optimize the monitoring of Multiple Sclerosis using smartphones (floodlight open study)

  Butzkueven, H. & Gresle, M.

  31/03/19 → 31/03/24

  Project: Research

• NHMRC Equipment Grant - Quanterix SIMOA HD-1 Analyser

  Shultz, S. (Primary Chief Investigator (PCI)), Kwan, P. (Chief Investigator (CI)), Medcalf, R. (Chief Investigator (CI)), O'Brien, T. (Chief Investigator (CI)), Mitra, B. (Chief Investigator (CI)), Coughlan, M. (Chief Investigator (CI)), Jones, N. (Chief Investigator (CI)), Van Der Walt, A. (Chief Investigator (CI)), Butzkueven, H. (Chief Investigator (CI)), Semple, B. (Chief Investigator (CI)) & Hutton, E. (Chief Investigator (CI))

  Monash University – Internal Faculty Contribution, Monash University – Internal Department Contribution

  1/01/19 → 31/12/19

  Project: Research

• Next generation biomarkers for multiple sclerosis

  Van Der Walt, A. (Primary Chief Investigator (PCI)), Kolbe, S. (Chief Investigator (CI)), Butzkueven, H. (Chief Investigator (CI)), Kalincik, T. (Chief Investigator (CI)) & Kilpatrick, T. J. (Chief Investigator (CI))

  Biogen Australia Pty Ltd

  1/01/19 → 15/12/23

  Project: Research

• PrevANZ: Phase IIb Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Trial of Vitamin D3 in Patients with a First Demyelinating Event.

  Butzkueven, H. (Primary Chief Investigator (PCI))

  5/12/18 → 31/12/20

  Project: Research

• PhD Project: Altered Vitamin D responsiveness in Multiple Sclerosis Immune Cells.

  Butzkueven, H. (Chief Investigator (CI)), Van Der Walt, A. (Primary Chief Investigator (PCI)), Stankovich, J. (Chief Investigator (CI)), Jokubaitis, V. (Chief Investigator (CI)) & Monif, M. (Chief Investigator (CI))

  Roche Products Pty Ltd (trading as Roche Australia)

  16/10/18 → 1/01/20

  Project: Research

• Prospective clinic and home-based serial monitoring of cognition in relapsing-remitting multiple sclerosis.

  Van Der Walt, A. (Primary Chief Investigator (PCI)) & Butzkueven, H. (Chief Investigator (CI))

  13/09/18 → 13/11/22

  Project: Research

• Mark Pennycook Foundation Research Donation

  Butzkueven, H.

  22/06/18 → 1/07/19

  Project: Research

• Characterizing the effects of vitamin D supplementation on immune gene expression in patients with a clinically isolated syndrome.

  Butzkueven, H. (Primary Chief Investigator (PCI)), Taylor, B. V. (Chief Investigator (CI)) & Lucas, R. M. (Chief Investigator (CI))

  1/01/18 → 31/12/19

  Project: Research

• Improving Multiple Sclerosis treatment outcomes

  Butzkueven, H. (Primary Chief Investigator (PCI))

  National Health and Medical Research Council (NHMRC) (Australia)

  1/01/18 → 31/12/19

  Project: Research

• Multiple Sclerosis Clinical Trials

  Butzkueven, H.

  1/01/15 → 31/12/20

  Project: Research

• Randomised Control Trial to determine whether nurse-initiated management improves bladder and bowel function in people with Multiple Sclerosis

  Kurczycki, L. & Butzkueven, H.

  Multiple Sclerosis Research Australia (trading as National Multiple Sclerosis Research Foundation Limited)

  1/01/14 → 31/12/14

  Project: Research

• Randomised Control Trial to determine whether nurse-initiated management improves bladder and bowel function and quality of life in people with Multiple Sclerosis

  Butzkueven, H. & Kurczycki, L.

  Multiple Sclerosis Research Australia (trading as National Multiple Sclerosis Research Foundation Limited)

  1/01/14 → 31/12/15

  Project: Research

• The multi-national Gilenya Pregnancy exposure registry in multiple sclerosis

  Butzkueven, H.

  1/05/13 → 31/03/17

  Project: Research

• Phase Iib Randomised double blind placebo controlled dose ranging trial of Vitamin D3 in patients with a first Demyelinating event

  Butzkueven, H.

  1/04/13 → 1/11/16

  Project: Research

• A multicentre, randomised, double blind, parallel group, placebo controlled variable treatment duration study evaluating the efficacy and safety of Piponimod (BAF312) in patients with secondary

  Butzkueven, H.

  18/02/13 → 29/05/14

  Project: Research

• Long-term, prospective, multinational prallel-cohort study monitoring safety in patients with MS newly started with fingolimod once daily or treated with another approved disease-modifying therapy

  Butzkueven, H.

  1/10/12 → 22/06/15

  Project: Research

• A multicentre open-label non-randomised parallel group clinical trial to assess the efficacy of Fingolimod in naive patients v Fingolimod in patients previously treated with interferons or glatiramer

  Butzkueven, H.

  25/06/12 → 1/12/13

  Project: Research

• A multicentre, single arm, open-label, phase IIIb study to evaluate the safety and antigenicity of Rebif (IFN-beta-1a) in subjects with relapsing forms of multiple sclerosis

  Butzkueven, H. & Gibson, P.

  1/08/05 → 25/12/07

  Project: Research